Combination Therapy With Sintilimab and Anlotinib for Advanced Undifferentiated Pleomorphic Sarcoma: A Case Report and Literature Review
Yan Chen, Ronghua Chu · 2026
Read Combination Therapy With Sintilimab and Anlotinib for Advanced Undifferentiated Pleomorphic Sarcoma: A Case Report and Literature Review by Yan Chen, Ronghua Chu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13286876.txt.
Description
Yan Chen and Ronghua Chu report an immunotherapy pairing that shrank a stubborn sarcoma in a case report published in 2026. The high-grade leg sarcoma of a 73-year-old woman, removed in 2022 with positive margins, returned two years later, invaded the shin bone, and seeded a lung spot. Standard chemotherapy made her too ill to continue, and after a year without treatment the leg tumor ulcerated down to bone.
Following amputation for local control, she received sintilimab, an immune checkpoint antibody, together with the vessel-targeting drug anlotinib. Her lung metastases shrank dramatically, scoring a partial response with a 76.6% reduction in tumor burden. The authors present the combination as a candidate route for advanced patients of this sarcoma type who cannot tolerate chemotherapy, while calling for proper trials.
Catalog record
| CREATOR | Yan Chen, Ronghua Chu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18554 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |